

Methodology Note on Transfers of Value (ToV) to UK Health Professionals, Other Relevant Decision Makers and Healthcare Organisations

In accordance with the requirements of the Association of the British Pharmaceutical Industry (ABPI) 2021 Code of Practice for the Pharmaceutical Industry, Alliance Pharmaceuticals Limited (Alliance) has publicly disclosed certain transfers of value made directly or indirectly to health professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs) in the UK.

This note summarises the methodologies used by Alliance in preparing these ToV disclosures.

Alliance transfers of value include:

- Funding for Collaborative working, including Joint working.
- Donations and grants provided to healthcare organisations, institutions, and other organisations.
- Fees and expenses paid for contracted services between Alliance and institutions, organisations or associations of health professionals.
- Support of attendance by health professionals and other relevant decision makers at events/meetings whether paid directly, indirectly or via another party. Fees and expenses paid to health professionals and other relevant decision makers, or to their employers on their behalf.
- Sponsorship, including contributions to costs related to events/meetings paid to healthcare organisations or to organisations managing events on their behalf, which may include support of health professionals not known to the company via the healthcare organisation by way of registration fees, accommodation and travel.

For the purposes of this disclosure, Alliance has collectively defined donations and grants as providing funds, benefits-in-kind or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to the benefit of Alliance in return. In general, grants are the provision of funds. Donations are physical items, services or benefits in-kind which may be offered or requested. Product donations are valued at list price. Donations to HCOs that are funded by employee contributions are not disclosed.

Sponsorship is defined as a contribution, financial or otherwise, in whole or in part provided by or on behalf of Alliance, towards an activity (including an event/meeting or material) performed, organised, created etc by a healthcare organisation, patient organisation or other independent organisation.

Consent from the HCPs / ORDMs to disclose these transfers of value have been obtained on an individual activity basis through signed consultancy agreements or other written communication. Where HCP and ORDM recipients of transfers of value cannot be identified

for legal reasons, the amount attributable to such transfers have been disclosed on an aggregate basis. The number of recipients involved have been stated together with the percentage of all recipients that they represent and the aggregate amount attributable to transfers of value to such HCP and ORDM recipients.

Only transfers of value relating to prescription medicines (POM) and over-the-counter medicines (where the aim of promotion to HCP's is to encourage prescription or supply) have been included within this disclosure, and any transfers of value relating solely to over-the-counter medicines (with the aim to encourage purchase by MoP), medical devices, cosmetics or food supplements have not been included in this disclosure.

Where an activity involves transfers of value relating to both prescription medicines or OTC medicines promoted with the aim of prescription/supply, and to other categories of products (e.g., P, GSL etc.), only the Alliance budgetary allocation relating to the prescription medicine or OTC medicine promoted with the aim of prescription/supply will be included in this disclosure. Where there was no split in budgetary allocation, the total of the transfer of value has been split equally by the number of brands that were involved at that activity. In these instances, the split of budgetary allocation for such activities is available on request.

Disclosed payments relate to transfers of value where the payment transaction was completed in 2022. Any transfers of value relating to activity that spans two calendar years are disclosed in the year the transfer of value is completed.

All transfers of value are disclosed in Great British Pounds (£). Where a payment was fulfilled in another currency, the value was converted into Great British Pounds based on the exchange rate at the time of payment. VAT has been included in the disclosed payments.

No non-monetary transfers of value were made by Alliance in 2022.

Alliance paid a total of £800 in fees and expenses working with HCO's or HCP's in 2022 relating to the planning or conduct of R&D, which has been disclosed in the R&D aggregate total.

No transfers of value relating to collaborative working with other pharmaceutical companies or healthcare organisations were made by Alliance in 2022.

Contact details for ToV related enquiries: medinfo@alliancepharma.co.uk

Date of preparation: March 2023